Press Announcements > FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults

Press Announcements > FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults

FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults

New quick testing option to help reduce need for CT scans, radiation exposure for patients

The U.S. Food and Drug Administration today permitted marketing of the first blood test to evaluate mild traumatic brain injury (mTBI), commonly referred to as concussion, in adults. The FDA reviewed and authorized for marketing the Banyan Brain Trauma Indicator in fewer than 6 months as part of its Breakthrough Devices Program. Continue reading.

Press Announcements > FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults